Apnimed Appoints Kevin Lind as CEO

Apnimed Inc., a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies, has appointed Kevin Lind as Chief Executive Officer (CEO), effective June 2, 2026, as part of a planned leadership transition. He succeeds Company founder Lawrence “Larry” G. Miller, MD, who has served as CEO since 2018 and will transition to Vice Chair of the Board.

Experience

Lind brings over 25 years of biopharmaceutical experience to the CEO role and has served as Chairperson of the Apnimed Board since March 2025. Paul Sekhri has been appointed independent Chair of the Apnimed Board of Directors, succeeding Lind, who will continue to serve as a director on the Board following his appointment as CEO.

Most recently, Lind co-founded Longboard Pharmaceuticals and served as Longboard’s President and CEO through its acquisition by Lundbeck for $2.6B. He will lead Apnimed as the company builds its capabilities towards a potential commercialization of AD109 for Obstructive Sleep Apnea (OSA), which is now in the regulatory phase of development in the U.S.

“I am honored to lead Apnimed at such a critical moment and look forward to working with the team to make a meaningful difference for people living with OSA,” Lind remarked. “In just a few years, the Company has evolved into an exciting late-stage pharmaceutical company built around its lead asset, AD109, which I believe represents a compelling opportunity to address a significant unmet need in OSA. With the AD109 New Drug Application (NDA) now submitted and a potential PDUFA target action date expected in the first quarter of 2027, we are progressing commercial readiness for this important asset.”